Therapeutic options for acute myelogenous leukemia
Open Access
Abstract
BACKGROUND General therapeutic options for patients with acute myelogenous leukemia (AML) are reviewed and specific new therapies are described. METHODS Data in this review came from the published literature and the M. D. Anderson Cancer Center's acute leukemia database. RESULTS Outcome following standard therapy of AML is so variable that is best to speak of a range of outcomes determined by various prognostic factors. Therapy can (and usually does) fail because of treatment‐induced mortality or (more usually) resistance to therapy. Performance status and age are the principal predictors of early death, whereas cytogenetics, a history of abnormal blood counts, and MDR1 expression are predictors of resistance. Using this information, physicians can categorize patients into those in whom 1) standard therapy is indicated, 2) either standard or investigational therapy is appropriate, and 3) investigational therapy is indicated. The majority of even newly diagnosed patients belong to Group 3. The availability of allogeneic or autologous transplantation does not alter this conclusion. Investigational therapies have been developed that are directed against the CD33 surface antigen, the multidrug‐resistant MDR1 protein, and other targets. Because of the number of new therapies clinical research in AML should emphasize pilot trials rather than traditionally large Phase III studies. CONCLUSIONS Most patients with newly diagnosed AML should be offered investigational regimens. Cancer 2001;92:1059–73. © 2001 American Cancer Society.Keywords
This publication has 50 references indexed in Scilit:
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- Transplantation in First Remission of Acute Myeloid LeukemiaNew England Journal of Medicine, 1998
- Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) by All Transretinoic Acid (ATRA) Combined with Chemotherapy: The European ExperienceLeukemia & Lymphoma, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patientsBritish Journal of Haematology, 1994
- A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluationStatistics in Medicine, 1993
- The effect of chemotherapy on acute leukemia in the humanJournal of Chronic Diseases, 1961